In Brief: Gilead HIV Trials On Hold Over Safety Signal

Hold Affects Two Phase II/III Trials And Three Phase I Trials

The FDA has paused Gilead’s HIV trials of GS-1720 and GS-4182 over safety concerns. The company’s upcoming PrEP PDUFA looks to be unaffected.

Gilead
Gilead

More from Clinical Trials

More from Therapy Areas